Oncosec Medical Cmn (ONCS) 1.69 $ONCS OncoSec Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Oncosec Medical Cmn (ONCS) 1.69 $ONCS

OncoSec Announces Peer-Reviewed Publication of T-Cell Exhaustion Marker to Predict Response to Anti-PD-1 Therapy in Melanoma
PR Newswire - Mon Aug 15, 3:01PM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the publication of research showing that partially exhausted CD8+ cells infiltrating melanoma tumors accurately predicted most patients' responses to anti-PD-1 therapies. The findings, published in the Journal of Clinical Investigation, show that the response to pembrolizumab strongly correlated to the percent of CD8+ tumor-infiltrating lymphocytes (TILs) that expressed high levels of both PD-1 and CTLA-4. The study was led by University of California, San Francisco (UCSF) researchers and physicians. This exhaustion marker is currently being used to select patients for the ongoing Phase II investigator-sponsored clinical trial evaluating the combination of OncoSec's investigational therapy, ImmunoPulse® IL-12, and the approved anti-PD-1 therapy, pembrolizumab, in patients with unresectable metastatic melanoma.
ONCS: 1.69 (-0.03)

OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2016
PR Newswire - Thu Jun 09, 3:01PM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced key corporate objectives as well as financial results for the third quarter and year to date ended April 30, 2016.
ONCS: 1.69 (-0.03)

OncoSec Collaborators Present Results of Novel T-Cell Exhaustion Marker to Predict Response to Anti-PD-1 Monotherapy
PR Newswire - Mon Jun 06, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that its collaborators at the University of California San Francisco (UCSF) presented results at the American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating the utility of a T-cell exhaustion marker to predict response to anti-PD-1 monotherapies. Authors of this poster discussion session from UCSF include Adil Daud, MD, Alain Algazi, MD, and Michael Rosenblum, MD, PhD. This "low-tumor infiltrating lymphocyte" (TIL) marker is currently being used to select patients for the ongoing Phase II investigator-sponsored clinical trial evaluating the combination of OncoSec's investigational therapy, ImmunoPulse(TM) IL-12, and the approved anti-PD-1 therapy, pembrolizumab, in patients with unresectable metastatic melanoma.
ONCS: 1.69 (-0.03)

OncoSec Medical Incorporated's CEO Punit Dhillon Interviewed by The Life Sciences Report
Marketwire Canada - Thu Jun 02, 9:58AM CDT
SAN FRANCISCO, CA--(Marketwired - June 02, 2016) - Cancer patients often receive multiple rounds of chemotherapy, with new drugs incorporated into treatment programs as tumors develop resistance. OncoSec Medical Incorporated's (NASDAQ: ONCS) Punit Dhillon describes how his company is challenging that paradigm with a proprietary platform that delivers therapeutic agents directly to the tumor, while also laying a foundation for expanded use of combination immunotherapies at the forefront of cancer treatment.
ONCS: 1.69 (-0.03)

OncoSec to Present at Scientific and Investment Conferences in June
PR Newswire - Wed Jun 01, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members of its leadership team will be making presentations at several high-profile events in June, including:
ONCS: 1.69 (-0.03)

OncoSec Closes $10 Million At-The-Market Registered Direct Offering
PR Newswire - Thu May 26, 7:12PM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that it has closed its previously announced at-the-market registered direct offering with a single healthcare dedicated institutional fund for the purchase of 5,509,642 shares of its common stock at a price of $1.815, or pre-funded warrants in lieu thereof at a price of $1.805, and warrants to purchase up to an aggregate of 5,509,642 shares of common stock at an exercise price of $1.69 per share for a term of 9 years. The warrants are immediately exercisable on the date of issuance. The offering closed on May 26, 2016.
ONCS: 1.69 (-0.03)

OncoSec Announces $10 Million At-The-Market Registered Direct Offering
PR Newswire - Mon May 23, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it has entered into a definitive agreement with a single healthcare dedicated institutional fund to purchase approximately $10 million of securities in an at-the-market registered direct offering. OncoSec has agreed to sell to such investors an aggregate of 5,509,642 shares of its common stock, or pre-funded warrants in lieu thereof, at a price of $1.815 per share. Additionally, investors will receive warrants to purchase up to an aggregate of 5,509,462 shares of common stock at an exercise price of $1.69 per share for a term of 9 years. The warrants are immediately exercisable on the date of issuance.
ONCS: 1.69 (-0.03)

OncoSec to Host Third Quarter Financial Results Conference Call on June 9, 2016
PR Newswire - Wed May 18, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that the Company will host its fiscal third quarter 2016 financial results conference call on Thursday, June 9 at 1:15 PM PT/4:15 PM ET. To listen to the conference call, please dial (877) 731-1960 and use conference ID number: 4148915. An archived version of the presentation will be available for 90 days on the "Investors" section of OncoSec's website: ir.oncosec.com/events.
ONCS: 1.69 (-0.03)

4 Promising Small Cap Stocks That You Need To Know About
ACCESSWIRE - Wed Apr 20, 9:08AM CDT
NEW YORK, NY / ACCESSWIRE / April 20, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. OCLS, ONCS, CARA and UNXL are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CARA: 5.42 (-0.08), UNXL: 1.47 (-0.02), ONCS: 1.69 (-0.03), OCLS: 4.09 (-0.03)

OncoSec Presents Positive Melanoma Clinical Data at American Association for Cancer Research (AACR) Annual Meeting 2016
PR Newswire - Tue Apr 19, 3:45PM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented long-term, follow-up data of patients who were treated with its investigational therapy ImmunoPulse(TM) IL-12 and later went on to receive an anti-PD-1/PD-L1 therapy. These data suggest that ImmunoPulse(TM) IL-12 may prime and enhance response rates to PD-1/PD-L1 blockade. Alain Algazi, MD, skin cancer specialist in the Melanoma Center at the UCSF Helen Diller Family Comprehensive Cancer Center, presented the findings in an oral presentation entitled "Intratumoral electroporation of plasmid IL-12 can prime response to anti-PD1/PD-L1 blockade in patients with Stage III/IV-M1a melanoma" (Abstract #CT134) at the American Association of Cancer Research (AACR) Annual Meeting in New Orleans, LA.
ONCS: 1.69 (-0.03)

OncoSec and Heat Biologics Present Data at the American Conference for Cancer Research (AACR) Annual Meeting
PR Newswire - Mon Apr 18, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced that preclinical data from its collaboration with Heat Biologics, Inc. ("Heat" focused on evaluating the combination of immunotherapy platforms were presented yesterday at the American Conference for Cancer Research (AACR) Annual Meeting (www.aacr.org).
HTBX: 1.41 (-0.10), ONCS: 1.69 (-0.03)

OncoSec to Host Webcast and Panel Discussion on New Melanoma Clinical Data
PR Newswire - Wed Apr 13, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will host a webcast to provide an overview and panel discussion regarding new clinical data that will be featured as an oral presentation at the upcoming American Association of Cancer Research (AACR) Annual Meeting. The webcast will be held on Wednesday, April 20, 2016 at 11:00 AM ET/8:00 AM PT.
ONCS: 1.69 (-0.03)

OncoSec Announces Poster Presentation with Heat Biologics, Inc. at the American Association for Cancer Research (AACR) Annual Meeting 2016
PR Newswire - Tue Apr 12, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that preclinical results from OncoSec's collaboration with Heat Biologics, Inc. will be featured as a poster presentation at the upcoming American Association of Cancer Research (AACR) Annual Meeting to be held on April 16-20, 2016 in New Orleans, LA.
ONCS: 1.69 (-0.03)

Trending Stocks: We've Found Four to Observe on Tuesday, March 22nd
ACCESSWIRE - Tue Mar 22, 10:09AM CDT
MIAMI, FL / ACCESSWIRE / March 22, 2016 / Top Nasdaq Stocks is issuing a report on three stocks to watch. MTSL, ONCS, COOL, and CTRV have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
CTRV: 1.15 (+0.03), COOL: 3.83 (-0.17), ONCS: 1.69 (-0.03), MTSL: 1.17 (-0.04)

OncoSec to Present at Prominent Investment Conferences in February
PR Newswire - Wed Feb 03, 5:00AM CST
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members of its leadership team will be making presentations at several high-profile events in February, including:
ONCS: 1.69 (-0.03)

Immunotherapy Inside the Cell Interview by The Life Sciences Report
Marketwired - Fri Jan 08, 8:00AM CST
Targeting diseases from inside the cell could be medicine's version of the dawn of the Internet. Or, as newsletter writer Chen Lin describes it, advances from companies like Sorrento Therapeutics Inc. to introduce autologous immunotherapy intracellularly "opens a whole dimension." Dorman Followwill of Frost & Sullivan suggests this new approach could shift the focus from "therapy" to "cure," with rewards for the companies leading the way. In this article, The Life Sciences Report explores the possibilities of these new technologies -- and the prospects for companies like Sorrento, Inovio Pharmaceuticals Inc. and OncoSec Medical Inc. -- with Lin, Followwill and Ram Selvaraju of Rodman and Renshaw.
ONCS: 1.69 (-0.03), SRNE: 6.66 (+0.10)

OncoSec Opens New Headquarters and Research Facility in San Diego
PR Newswire - Thu Dec 17, 12:01PM CST
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the Company consolidated its three previous offices into one new headquarters and research facility, developed by Alexandria Real Estate Equities, Inc., in Sorrento Mesa, San Diego. As a result of the Company's growth over the past year, OncoSec moved into a new office that houses over 50 employees and all of the Company's discovery research, clinical, and administrative activities under one roof.
ARE: 110.09 (-0.20), ONCS: 1.69 (-0.03)

OncoSec incurs higher net loss of USD7.0m for Q1 fiscal 2016
M2 - Wed Dec 09, 5:50AM CST
Biotechnology company OncoSec Medical (NasdaqCM:ONCS) disclosed on Tuesday that it recorded a net loss of USD7.0m (USD0.47 per share) for the Q1 fiscal year ended 31 July 2016.
ONCS: 1.69 (-0.03)

OncoSec Announces First Quarter Results for Fiscal Year End 2016
PR Newswire - Tue Dec 08, 5:00AM CST
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the first quarter of fiscal year ended July 31, 2016.
ONCS: 1.69 (-0.03)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 283

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 229

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 266

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 238

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 18

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 286

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 131

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Beyond Meat Partners with Hard Rock Cafe for Burger Launch

Updated Category News Views 432

Beyond Meat and Hard Rock Cafe Collaboration Beyond Meat, Inc. (NASDAQ: BYND), an innovator in plant-based proteins, is excited to announce a partnership with Hard Rock Cafe, introducing the newest Beyond Burger across all its North American locations. This initiative allows diners to swap any beef burger from Hard Rock's core and kids' menus for the delicious and...

Continue Reading
ATEC Water Systems Welcomes Industry Leader Steve Green

Updated Category News Views 299

ATEC Water Systems welcomed Steve Green as their new Chief Commercial Officer back in 2024, shaking things up under the Cadiz, Inc. (NASDAQ: CDZI) umbrella. Traders watched closely; this wasn't just a run-of-the-mill hire but rather a strategic move aimed at revitalizing the company's trajectory in a crowded market. With Steve's extensive background in the water industry,...

Continue Reading
Mission Critical Group Welcomes Mark Feasel as VP of Sales

Updated Category News Views 249

Mission Critical Group Appoints New Vice President of Sales Mission Critical Group (MCG), a leader in critical power infrastructure solutions, is excited to announce the appointment of industry veteran Mark Feasel as the Vice President of Sales in the Commercial and Innovation Division. With this strategic addition, MCG aims to enhance its sales strategy and broaden its...

Continue Reading
Ascot Resources Explores Alternative TSXV Listing Options

Updated Category News Views 165

Ascot Resources Faces Delisting from TSX Ascot Resources Ltd., a Canadian mining company headquartered in Vancouver, is going through significant changes regarding its stock listings. Recently, the Continued Listing Committee of the Toronto Stock Exchange (TSX) informed Ascot that its common shares are set to be delisted at the market's close on a specified date. This...

Continue Reading
Albany International Corporation Faces Legal Scrutiny Amid Stockholder Concerns

Updated Category News Views 194

Introduction to the Investigation Albany International Corporation is currently experiencing legal scrutiny as concerns arise among stockholders regarding the company's financial performance. Recently, the law firm Bragar Eagel & Squire, P.C. has stepped in, urging investors who may have suffered losses in Albanian stocks to reach out for assistance. The firm seeks to...

Continue Reading